In Silico and In Vitro Studies for Benzimidazole Anthelmintics Repurposing as VEGFR-2 Antagonists: Novel Mebendazole-Loaded Mixed Micelles with Enhanced Dissolution and Anticancer Activity. (2022)

Peer-Reviewed Study · Ayman Abo Elmaaty; Khaled M Darwish; Amani Chrouda et al. · January 11, 2022

Ayman Abo Elmaaty et al., 2022-01-11: Molecular docking and dynamics study proposing mebendazole, fenbendazole and albendazole as VEGFR-2 antagonists, with in vitro testing of mebendazole-loaded mixed micelles.

Among the tested compounds, fenbendazole (FBZ, 1), mebendazole (MBZ, 2), and albendazole (ABZ, 3) were proposed as potential VEGFR-2 antagonists.

Ayman Abo Elmaaty et al., 2022-01-11: Molecular docking and dynamics study proposing mebendazole, fenbendazole and albendazole as VEGFR-2 antagonists, with in vitro testing of mebendazole-loaded mixed micelles. Study type: in silico docking/molecular dynamics plus in vitro cell viability (HUH7, A549, MCF7). N: not applicable. Country: Egypt (Port Said University). Dose: not stated in the abstract text captured. Funder: not stated in the record. Declared conflicts: 'The authors declare no competing financial interest.' PARTLY because the VEGFR-2 claim here is computational prediction, not measured kinase inhibition; the experimental work concerns a micellar formulation. Study type: lab.